Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mitochondrial amidoxime‐reducing component 1 p. Ala165Thr increases protein degradation mediated by the proteasome

20 Feb 2024

Abstract excerpt

OBJECTIVE: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a global health concern with no effective and specific drug treatment available. The rs2642438 minor allele in mitochondrial amidoxime-reducing component 1 (MARC1) results in an aminoacidic substitution (p.Ala165Thr) and associates with protection against MASLD. However, the mechanisms behind this protective effect are unknown. In this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Endoplasmic Reticulum Stress and Disease
Share to Liver Disease Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mitochondrial Function and Pathology

Source

Identifiers

PMID: 38375985
DOI: 10.1111/liv.15857

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mitochondrial amidoxime‐reducing component 1 p. Ala165Thr increases protein degradation mediated by the proteasomePMID 38375985Read ↗

Biochemical and functional characterization of the p.A165T missense variant of mitochondrial amidoxime-reducing component 1 in HepG2 cellsSemantic proximity Read ↗

Divergent role of Mitochondrial Amidoxime Reducing Component 1 (MARC1) in human and mouseSemantic proximity Read ↗

Loss of mitochondrial amidoxime-reducing component 1 (mARC1) prevents disease progression by reducing fibrosis in multiple mouse models of chronic liver diseaseSemantic proximity Read ↗

Downregulation of the MARC1 p.A165 risk allele reduces hepatocyte lipid content by increasing beta-oxidation.Semantic proximity Read ↗

A missense variant in Mitochondrial Amidoxime Reducing Component 1 gene and protection against liver diseaseSemantic proximity Read ↗

A missense variant in Mitochondrial Amidoxime Reducing Component 1 gene and protection against liver disease.Semantic proximity Read ↗

Fatty liver disease protective MTARC1 p.A165T variant reduces the protein stability of MTARC1Semantic proximity Read ↗

A genome-first approach to mortality and metabolic phenotypes in MTARC1 p.Ala165Thr (rs2642438) heterozygotes and homozygotes.Semantic proximity Read ↗

The clinically relevant MTARC1 p.Ala165Thr variant impacts neither the fold nor active site architecture of the human mARC1 proteinSemantic proximity Read ↗

Hepatocyte mARC1 promotes fatty liver diseaseSemantic proximity Read ↗

Evaluation of MARC1 Variants and Extracellular Vesicle Cytokeratin-18 as Predictive Biomarkers in a group of Egyptian MASLD and MASH patientsSemantic proximity Read ↗

The common p.Ile291Val variant of ERLIN1 enhances TM6SF2 function and is associated with protection against MASLD.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.